JPWO2019236965A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019236965A5
JPWO2019236965A5 JP2020567757A JP2020567757A JPWO2019236965A5 JP WO2019236965 A5 JPWO2019236965 A5 JP WO2019236965A5 JP 2020567757 A JP2020567757 A JP 2020567757A JP 2020567757 A JP2020567757 A JP 2020567757A JP WO2019236965 A5 JPWO2019236965 A5 JP WO2019236965A5
Authority
JP
Japan
Prior art keywords
hvr
amino acid
seq
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020567757A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021526794A (ja
JP7382970B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/035990 external-priority patent/WO2019236965A1/en
Publication of JP2021526794A publication Critical patent/JP2021526794A/ja
Publication of JPWO2019236965A5 publication Critical patent/JPWO2019236965A5/ja
Application granted granted Critical
Publication of JP7382970B2 publication Critical patent/JP7382970B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020567757A 2018-06-08 2019-06-07 抗Siglec-7抗体及びその使用方法 Active JP7382970B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682439P 2018-06-08 2018-06-08
US62/682,439 2018-06-08
PCT/US2019/035990 WO2019236965A1 (en) 2018-06-08 2019-06-07 Anti-siglec-7 antibodies and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2021526794A JP2021526794A (ja) 2021-10-11
JPWO2019236965A5 true JPWO2019236965A5 (zh) 2022-06-09
JP7382970B2 JP7382970B2 (ja) 2023-11-17

Family

ID=67003745

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020567757A Active JP7382970B2 (ja) 2018-06-08 2019-06-07 抗Siglec-7抗体及びその使用方法

Country Status (13)

Country Link
US (1) US20210246204A1 (zh)
EP (1) EP3801767A1 (zh)
JP (1) JP7382970B2 (zh)
KR (1) KR20210030341A (zh)
CN (1) CN112512638A (zh)
AU (1) AU2019282778A1 (zh)
BR (1) BR112020024919A2 (zh)
CA (1) CA3100626A1 (zh)
EA (1) EA202092595A1 (zh)
IL (1) IL279227A (zh)
MA (1) MA52764A (zh)
MX (1) MX2020013172A (zh)
WO (1) WO2019236965A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018525999A (ja) 2015-08-28 2018-09-13 アレクトル エルエルシー 抗Siglec−7抗体及びその使用方法
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
ATE108068T1 (de) 1987-09-23 1994-07-15 Bristol Myers Squibb Co Antikörper-heterokonjugate zur töting von hiv- infizierten zellen.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE144793T1 (de) 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
KR0149181B1 (ko) 1990-06-29 1998-08-17 데이비드 알, 맥지 형질전환된 미생물에 의한 멜라닌의 제조방법
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2122732C (en) 1991-11-25 2008-04-08 Marc D. Whitlow Multivalent antigen-binding proteins
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1997011971A1 (en) 1995-09-28 1997-04-03 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
EP0942968B1 (en) 1996-12-03 2008-02-27 Amgen Fremont Inc. Fully human antibodies that bind EGFR
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU782626B2 (en) 1999-10-04 2005-08-18 Medicago Inc. Method for regulating transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US20040119010A1 (en) 2002-11-01 2004-06-24 The Regents Of The University Of Colorado Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
EA200701211A1 (ru) 2004-12-31 2007-12-28 Дженентек, Инк. Полипептиды, которые связываются с br3, и их применение
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
EP2359834B1 (en) 2006-03-15 2016-11-09 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
JP5885664B2 (ja) 2009-09-25 2016-03-15 ゾーマ テクノロジー リミテッド スクリーニング法
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
US20170306014A1 (en) 2014-09-10 2017-10-26 Innate Pharma Cross reactive siglec antibodies
JP2018525999A (ja) 2015-08-28 2018-09-13 アレクトル エルエルシー 抗Siglec−7抗体及びその使用方法
KR102581747B1 (ko) * 2016-07-01 2023-09-22 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 표적 세포 표면 편집을 위한 접합체
CN106831989A (zh) 2017-01-04 2017-06-13 中国人民解放军***军事医学研究所 人源抗唾液酸结合免疫球蛋白样凝集素‑7的抗体IgG及其应用
AU2019208025A1 (en) * 2018-01-11 2020-09-03 Allakos, Inc. Anti-Siglec-7 antibodies having reduced effector function

Similar Documents

Publication Publication Date Title
EP3822289A1 (en) Anti-sirp alpha antibody
JP2019500892A5 (zh)
CA3020864A1 (en) Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
US11202828B2 (en) Therapeutic SIRP-α antibodies
US20220098307A1 (en) Modified fc fragment, antibody comprising same, and application thereof
JP2020500540A5 (zh)
CA2986953A1 (en) Lag-3-binding molecules and methods of use thereof
JP2018518176A5 (zh)
JP2018518491A5 (zh)
RU2018126297A (ru) Антитела, нацеленные на cd32b, и способы их применения
JP2014509861A5 (zh)
JPWO2019129221A5 (zh)
US20180344829A1 (en) Siglec-10 antibodies
JP2021528063A (ja) 癌を処置するための組成物及び方法
US20230114801A1 (en) MINIATURE GUIDANCE AND NAVIGATION CONTROL (miniGNC) ANTIBODY-LIKE PROTEINS AND METHODS OF MAKING AND USING THEREOF
JPWO2019236965A5 (zh)
AU2021264006A1 (en) Therapeutic sirpalpha antibodies
JPWO2019195452A5 (zh)
JPWO2021119508A5 (zh)
JPWO2020185722A5 (zh)
JP7192042B2 (ja) Lag‐3結合分子及びその使用方法
JPWO2021213475A5 (zh)
RU2021127470A (ru) Анти-pd-l1 антитело и его применение
JPWO2020023920A5 (zh)
TW202241956A (zh) 新穎抗cd24抗體